Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Panos Kefalas"'
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Background: The experience of Kymriah® and Yescarta® provides real-world examples of how health-care systems approach and manage the reimbursement of one-off, high-cost, cell, and gene therapies, and the decision uncertainty and affordability chall
Externí odkaz:
https://doaj.org/article/8aa6054ae94a4c32955596128ead4211
Publikováno v:
Stem Cells Translational Medicine, Vol 6, Iss 8, Pp 1723-1729 (2017)
Abstract Cellular therapies and other regenerative medicines are emerging as potentially transformative additions to modern medicine, but likely at a staggering financial cost. Public health care systems’ budgets are already strained by growing and
Externí odkaz:
https://doaj.org/article/e48c15f8affc4c7fb3a473b286a28632
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Background: Cell and gene therapies are associated with uncertainty around their value claims at launch due to limitations of supporting clinical data; furthermore, their high costs present affordability issues for payers. Outcomes-based reimbursemen
Externí odkaz:
https://doaj.org/article/8fd1dbac609d4917a68fe286acc83c5a
Autor:
Jesper Jørgensen, Panos Kefalas
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Background: Outcomes-based reimbursement (OBR) can reduce decision uncertainty and accelerate patient access to cell and gene therapies, however, OBR is rarely applied in practice in England. Oncology is the therapy area with the most cell and gene t
Externí odkaz:
https://doaj.org/article/fc689d5d789540a4a82aab93298b9d7c
Autor:
Panos Kefalas, Omar Ali, Jesper Jørgensen, Nick Merryfield, Tim Richardson, Adam Meads, Laura Mungapen, Matthew Durdy
Publikováno v:
Journal of Market Access & Health Policy, Vol 6, Iss 1 (2018)
Background: Market access stakeholders consider the adoption of Managed Entry Agreements (MEAs), however a clearly described methodology to quantify their implementation burden is not available in the public domain. Objective: To quantify the cost of
Externí odkaz:
https://doaj.org/article/33372e50efcd4a9d80ada09aaf347d7c
Publikováno v:
Journal of Market Access & Health Policy, Vol 6, Iss 1 (2018)
Background: NICE in England, and ICER in the US both use cost-utility analyses (CUA) and budget impact analyses (BIA) to assess value for money and affordability, however the thresholds used differ greatly. Objective: To perform a cross-country compa
Externí odkaz:
https://doaj.org/article/c17a65ddee2144eda3fc43b9cb4bfe77
Autor:
Jesper Jørgensen, Panos Kefalas
Publikováno v:
Journal of Market Access & Health Policy, Vol 5, Iss 1 (2017)
Background: Cell and gene therapies have the potential to provide therapeutic breakthroughs, but the high costs of researching, developing, manufacturing and delivering them translate into prices that may challenge healthcare budgets. Various measure
Externí odkaz:
https://doaj.org/article/afa469b3f9a740b9bbd863f70804bf52
Publikováno v:
Regenerative Medicine. 17:767-782
The number of gene therapies in clinical trials and moving toward licensure is increasing. Most gene therapies are designed to achieve long-term effects, but at licensure the data to support claims of long-term durability are often limited, as long-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7fa33d1ad3782df4f510c6cc6c3d93d
https://doi.org/10.2217/rme-2021-0159
https://doi.org/10.2217/rme-2021-0159
Autor:
Panos Kefalas, Jesper Jørgensen
Publikováno v:
Regenerative medicine. 16(4)
Innovative reimbursement mechanisms have long been considered potential solutions to the data uncertainty associated with one-off, high-value gene therapies that have long-term therapeutic potential, combined with limited supporting evidence at launc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebeef977c744d09893e3b5d314195a2a
https://pubmed.ncbi.nlm.nih.gov/33847163
https://pubmed.ncbi.nlm.nih.gov/33847163
Publikováno v:
Journal of pharmaceutical sciences. 110(5)
As the cell and gene therapy field matures the powerful therapeutic potential of these innovative therapies is starting to be shown, particularly in the fields of oncology and childhood immune deficiency diseases. However, as more therapies enter lat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da2dedf7c952b0dfcef8b394f661fbf7
https://pubmed.ncbi.nlm.nih.gov/32918916
https://pubmed.ncbi.nlm.nih.gov/32918916